Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracey G Simon

Showing results (21-30 of 128) with videos related to

Pageof 13
Sort By:
Journal of Hepatology|May 19, 2022
Artificial intelligence for the prevention and clinical management of hepatocellular carcinomaJulien Calderaro, Tobias Paul Seraphin, Tom Luedde, et al.
Journal of Hepatology|August 20, 2014
Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis CTracey G Simon, Lindsay Y King, Hui Zheng, et al.
Digestive Diseases and Sciences|October 8, 2016
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of EzetimibeTracey G Simon, Kathleen E Corey, Raymond T Chung, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 15, 2017
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVESAdeel Ajwad Butt, Peng Yan, Tracey G Simon, et al.
Journal of Hepatology|August 21, 2023
Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort studyTracey G Simon, Bjorn Roelstraete, Hannes Hagström, et al.
Gut|October 10, 2020
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohortTracey G Simon, Bjorn Roelstraete, Hamed Khalili, et al.
Gut|September 7, 2021
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohortTracey G Simon, Bjorn Roelstraete, Hannes Hagström, et al.
Hepatology (Baltimore, Md.)|February 19, 2016
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVESTracey G Simon, Hector Bonilla, Peng Yan, et al.
Journal of the American College of Cardiology|January 14, 2022
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the WeekAlessandro Mantovani, Christopher D Byrne, Giovanni Benfari, et al.
Gut|December 15, 2022
Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver diseaseTracey G Simon, Bjorn Roelstraete, Naim Alkhouri, et al.
Pageof 13

Showing results (21-30 of 128) with videos related to

Sort By:
Pageof 13
Journal of Hepatology|May 19, 2022
Artificial intelligence for the prevention and clinical management of hepatocellular carcinomaJulien Calderaro, Tobias Paul Seraphin, Tom Luedde, et al.
Journal of Hepatology|August 20, 2014
Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis CTracey G Simon, Lindsay Y King, Hui Zheng, et al.
Digestive Diseases and Sciences|October 8, 2016
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of EzetimibeTracey G Simon, Kathleen E Corey, Raymond T Chung, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 15, 2017
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVESAdeel Ajwad Butt, Peng Yan, Tracey G Simon, et al.
Journal of Hepatology|August 21, 2023
Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort studyTracey G Simon, Bjorn Roelstraete, Hannes Hagström, et al.
Gut|October 10, 2020
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohortTracey G Simon, Bjorn Roelstraete, Hamed Khalili, et al.
Gut|September 7, 2021
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohortTracey G Simon, Bjorn Roelstraete, Hannes Hagström, et al.
Hepatology (Baltimore, Md.)|February 19, 2016
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVESTracey G Simon, Hector Bonilla, Peng Yan, et al.
Journal of the American College of Cardiology|January 14, 2022
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the WeekAlessandro Mantovani, Christopher D Byrne, Giovanni Benfari, et al.
Gut|December 15, 2022
Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver diseaseTracey G Simon, Bjorn Roelstraete, Naim Alkhouri, et al.
Pageof 13